Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOAR: Oral Testosterone Undecanoate in Hypogonadism
NCT02081300Phase 3Completed
- Sponsor
- Lipocine Inc
- Start
- Feb 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of TSX-011 in male hypogonadism (2 arms), sponsored by Lipocine Inc. Primary endpoint: Proportion of subjects who achieve a total testosterone concentration [Cavg] between 300 - 1140 ng/dL at 13 weeks. Started Feb 2014; status: completed.
02
Drugs
TSX-011
03
Conditions
male hypogonadism
Beyond the preview
Go deeper on NCT02081300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081300.